Dianthus Therapeutics CFO Ryan Savitz reports $11.23 million share disposal
DNTH•Dianthus Therapeutics EVP, CFO and CBO Ryan Savitz sold 124,042 common shares from Nov. 9 to 12, 2026, matching the number acquired through stock option exercises. He held no common shares after the transactions and retained options covering 176,884 shares.
1. Share transactions
Ryan Savitz sold 124,042 Dianthus Therapeutics common shares between Nov. 9 and 12, 2026, matching 124,042 shares he acquired through stock option exercises over the same period. After the transactions, Savitz held no common shares and retained stock options covering 176,884 shares.
